<DOC>
	<DOCNO>NCT00027716</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer block enzyme necessary tumor cell growth . PURPOSE : Phase II trial study effectiveness bortezomib treat patient advanced metastatic sarcoma .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Advanced Metastatic Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient advance metastatic sarcoma treat bortezomib . - Correlate level cyclins D1 , E , p21 ( WAF1 ) , p27 ( Kip1 ) , mdm^2 , p53 , Ki67 response patient treated drug . OUTLINE : This open-label , multicenter study . Patients stratify accord disease ( stratum I : soft tissue sarcoma specify stratum II , osteogenic sarcoma arise soft tissue , gastrointestinal stromal tumor v stratum II : Ewing 's sarcoma soft tissue bone , rhabdomyosarcoma , osteogenic sarcoma bone ) . ( Stratum I close accrual 10/17/03 . ) Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 21-41 patient accrue stratum I within 5-11 month 21-41 patient accrue stratum II within 10.5-22 month . ( Stratum I close accrual 10/17/03 . )</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm sarcoma Soft tissue metastasis locally recurrent disease Stratum I ( close accrual 10/17/03 ) : Soft tissue sarcoma specify stratum II Osteogenic sarcoma arise soft tissue gastrointestinal stromal tumor ( GIST ) Stratum II : Ewing 's sarcoma soft tissue bone ( measurable soft tissue metastasis present ) Rhabdomyosarcoma Osteogenic sarcoma bone ( measurable soft tissue metastasis present ) At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan Disease progression within past 3 month No prior active know brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % OR ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No peripheral vascular disease require surgical management No history congestive heart failure even medically control No angina pectoris even medically control No myocardial infarction within past year No cardiac arrhythmias No prior cerebrovascular event No prior transient ischemic attack No EKG evidence acute ischemia conduction abnormality ( e.g. , bifascicular block [ leave anterior hemiblock presence right bundle branch block ] second third degree atrioventricular block ) No history orthostatic hypotension Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biological composition study drug No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No malignancy within past 5 year except adequately treat basal cell skin cancer carcinoma situ cervix No symptomatic peripheral neuropathy great grade 1 PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover No concurrent biological immunological agent Chemotherapy : Stratum I ( close accrual 10/17/03 ) : At least 1 year since prior chemotherapy adjuvant neoadjuvant setting No prior chemotherapy Stratum II : No 1 prior chemotherapy regimen No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : Prior imatinib mesylate GIST ( stratum I close accrual 10/17/03 ) allow No concurrent investigational agent No concurrent commercial anticancer agent therapies No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>